Shares are on the rise in cancer technology company Physiomics after it announced a contract with a major global top 10 pharmaceutical client. The company's shares rose 10% to 7.98p by mid-afternoon on Friday in response to news of the new contract. The project, which will be completed in 2018, involves use of Physiomics' virtual tumour technology, which simulates tumour reactions to different treatments, in a pre-clinical setting and is understood to be worth approximately £70,000. Dr Jim ...Den vollständigen Artikel lesen ...
© 2018 LiveCharts.co.uk
